Obesity in schizophrenia: what can be done about it?

REFERENCES

• Allison DB, Mentore JL, Heo M, et al. Antipsychotic‐induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999; 156: 1686–1696
   PubMed Web of Science ®Google Scholar
• Taylor DM, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatria Scandinavica 2000; 101: 416–432
   PubMed Web of Science ®Google Scholar
• Coodin S. Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry 2001; 46: 549–555
   PubMed Web of Science ®Google Scholar
• Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 1999; 29: 697–701
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, National Center for Health Statistics. National Health Interview Survey. US Department of Health and Human Services, Hyattsville, MD 1993, CD‐ROM Series
   Google Scholar
• Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35: 205–219
   PubMed Web of Science ®Google Scholar
• Allison DB, Casey DE. Antipsychotic‐induced weight gain: a review of the literature. Journal of Clinical Psychiatry 2001; 62(Suppl. 7)22–31
   PubMed Web of Science ®Google Scholar
• Gothelf D, Falk B, Singer P, et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. American Journal of Psychiatry 2002; 159: 1055–1057
   PubMed Web of Science ®Google Scholar
• Wirshing DA, Pierre JM, Erhart SM, Boyd JA. Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatric Clinics of North America 2003; 26: 165–190
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. Journal of Clinical Psychiatry 2003; 64: 598–604
   PubMed Web of Science ®Google Scholar
• Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin 2000; 26: 903–912
   PubMed Web of Science ®Google Scholar
• Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone‐ and olanzapine‐treated inpatients: metabolic outcomes after 1 year. Journal of Clinical Psychiatry 2002; 63: 425–433
   PubMed Web of Science ®Google Scholar
• Green AI. Detection and management of comorbidity in patients with schizophrenia. Psychiatric Clinics of North America 2003; 26: 115–139
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry 2002; 59: 337–345
   PubMed Web of Science ®Google Scholar
• Strassnig M, Brar JS, Ganguli R. Body mass index and quality of life in community‐ dwelling patients with schizophrenia. Schizophrenia Research 2003; 62: 73–76
   PubMed Web of Science ®Google Scholar
• Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatric Services 2003; 54: 565–567
   PubMed Web of Science ®Google Scholar
• Gitlin MJ, Cochran SD, Jamison KR. Maintenance lithium treatment: side effects and compliance. Journal of Clinical Psychiatry 1989; 50: 127–131
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Isaacs I, Fuchs C, et al. Attenuation of olanzapine‐induced weight gain with reboxetine in patients with schizophrenia: a double‐blind, placebo‐controlled study. American Journal of Psychiatry 2003; 160: 297–302
   PubMed Web of Science ®Google Scholar
• Baptista T, Hernandez L, Prieto LA, Boyero EC, de Mendoza S. Metformin in obesity associated with antipsychotic drug administration: a pilot study. Journal of Clinical Psychiatry 2001; 62: 653–655
   PubMed Web of Science ®Google Scholar
• Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatidine for prevention of weight gain with olanzapine: a doubleclind placebo‐controlled trial. European Neuropsychopharmacology 2003; 13: 81–85
   PubMed Web of Science ®Google Scholar
• Winter KM, Ohlsen RI, Bell R, Pilowsky LS. Developing a healthy lifestyle/fitness programme for people with serious mental illness. Schizophrenia Research 2003; 60: 349
   Web of Science ®Google Scholar
• Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine‐related weight gain. Psychiatric Services 2001; 52: 967–969
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Perry E, Jaythilake K. Clozapine‐induced weight gain predicts improvement in psychopathology. Schizophrenia Research 2003; 59: 19–27
   PubMed Web of Science ®Google Scholar
• Sacchetti E, Guarneri L, Bravi D. H2 antagonist nizatidine may control olanzapine‐ associated weight gain in schizophrenic patients. Biological Psychiatry 2000; 48: 167–168
   PubMed Web of Science ®Google Scholar
• Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. American Journal of Psychiatry 2002; 159: 655–657
   PubMed Web of Science ®Google Scholar
• Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. European Neuropsychopharmacology 2001; 11: 181–182
   PubMed Web of Science ®Google Scholar
• Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Canadian Journal of Psychiatry 2000; 45: 198
   PubMed Web of Science ®Google Scholar
• Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine‐induced weight gain in schizophrenia. Journal of Clinical Psychiatry 2002; 63: 11
   Web of Science ®Google Scholar
• Blair SN. Exercise as a strategy to lose weight. Proceedings of the 9th International Congress on Obesity, Sao PauloBrazil, August, 2002
   Google Scholar
• Wadden TA, Berkowitz RI, Sarwer DB, Prus‐Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Archives of Internal Medicine 2001; 161: 218–227
   PubMed Web of Science ®Google Scholar
• James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356: 2119–2125
   PubMed Web of Science ®Google Scholar
• Van Baak M, Van Mil E, Astrup A, et al. Determinants of weight maintenance after weight loss in the STORM trial. Proceedings of the 9th International Congress on Obesity, Sao PauloBrazil, August, 2002
   Google Scholar
• Ravinet‐Trillou C, Arnone M, Delgorge C, et al. Anti‐obesity effect of SR141716, a CB1 receptor antagonist, in diet‐induced obese mice. American Journal of Physiologic Regulatory, Integrative and Comparative Physiology 2003; 284: R345–R353
   PubMed Web of Science ®Google Scholar